Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies

H Zetterberg, BB Bendlin - Molecular psychiatry, 2021 - nature.com
Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Tau PET imaging in neurodegenerative tauopathies—still a challenge

A Leuzy, K Chiotis, L Lemoine, PG Gillberg… - Molecular …, 2019 - nature.com
The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology

NJ Ashton, WS Brum, G Di Molfetta, AL Benedet… - JAMA …, 2024 - jamanetwork.com
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

TA Pascoal, J Therriault, AL Benedet, M Savard… - Brain, 2020 - academic.oup.com
Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the
criteria for the neuropathological diagnosis of Alzheimer's disease. It is expected that Braak …

18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases

DN Soleimani-Meigooni, L Iaccarino, R La Joie… - Brain, 2020 - academic.oup.com
Few studies have evaluated the relationship between in vivo 18F-flortaucipir PET and post-
mortem pathology. We sought to compare antemortem 18F-flortaucipir PET to …

A walk through tau therapeutic strategies

S Jadhav, J Avila, M Schöll, GG Kovacs… - Acta neuropathologica …, 2019 - Springer
Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease
and related human tauopathies. There is a growing body of evidence indicating that …

Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders

A Leuzy, R Smith, R Ossenkoppele, A Santillo… - JAMA …, 2020 - jamanetwork.com
Importance The diagnostic performance of second-generation tau positron emission
tomographic (PET) tracers is not yet known. Objective To examine the novel tau PET tracer …

[HTML][HTML] Biomarkers for tau pathology

M Schöll, A Maass, N Mattsson, NJ Ashton… - Molecular and Cellular …, 2019 - Elsevier
The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease

M Shulman, J Kong, J O'Gorman, E Ratti… - Nature aging, 2023 - nature.com
In Alzheimer's disease, the spread of aberrantly phosphorylated tau is an important criterion
in the Braak staging of disease severity and correlates with disease symptomatology. Here …

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia

MJ Pontecorvo, MD Devous, I Kennedy, M Navitsky… - Brain, 2019 - academic.oup.com
The advent of tau-targeted PET tracers such as flortaucipir (18F)(flortaucipir, also known as
18F-AV-1451 or 18F-T807) have made it possible to investigate the sequence of …